UNSPSC 51294209: Indeloxazine hydrochloride

This classification denotes an antidepressant agent with the molecular structure C14H17NO2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 15QZ6NE84E chemically known as morpholine, 2-((1h-inden-7-yloxy)methyl)-, hydrochloride, (+/-)-, but more commonly known as indeloxazine hydrochloride, which bears US NIH Compound Identifier 47517. European Medicines Agency schedules Indeloxazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02663MIG.

UNSPSC 51294209 Indeloxazine hydrochloride, a Commodity code, shows minimal recent activity in state and local procurement aligned to its specific chemical designation. The three most recent opportunities tagged to this code involve naloxone and safe drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products distributed through cooperative purchasing, and a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program — none of which target indeloxazine hydrochloride as a primary procurement objective. State and local issuers soliciting under pharmaceutical and OTC codes span county health departments, state HHS agencies, and multistate cooperative purchasing alliances, with work typically framed around broad pharmaceutical supply contracts rather than single-molecule active ingredients.

The geographic spread includes Florida, Texas, and Minnesota-led multistate cooperative purchasing serving Oregon and other participating jurisdictions. The Seminole County, Florida IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. The Texas Health and Human Services Commission posted an RFI (HHS0017013, response deadline April 3, 2026) exploring direct-to-manufacturer prescription programs to improve fulfillment efficiency. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with awarded contracts effective July 1, 2026, and a two-year initial term. The code appears to function as a categorical tag for pharmaceutical procurement rather than a driver of specific indeloxazine hydrochloride demand in recent solicitations.